Work

Lipophilic Emtricitabine prodrugs for targeting HIV reservoirs in mesenteric lymph nodes

Year: 2026
Type: dissertation
Abstract: Despite the great advances in the treatment of human immunodeficiency virus-1 (HIV-1), there is still no definitive standardised cure for it. While current antiretroviral therapy (ART) effectively suppresses viral load in plasma restoring CD4 cell count, cessation of treatment can result in viral rebound. The persistence of anatomical and cellular viral reservoirs established during primary infection stage is considered to be one of the main reasons behind this. Among these, gut-associated lymphoid tissue (GALT), in particular mesenteric lymph nodes, is a key reservoir due to its large population of CD4+ T cells. Poor penetration of antiretrovirals into these tissues, in particular into mesenteric lymph nodes, results in subtherapeutic local drug levels and prevents viral eradication. This work aimed to improve the delivery of the first line nucleoside reverse transcriptase inhibitor (NRTI) for HIV treatment emtricitabine ((−)-2'-deoxy-5-fluoro-3'-thiacytidine, FTC), to the HIV reservoirs within the mesenteric lymph nodes by means of a lipophilic prodrug approach combined with a lipid-based formulation. The rational for this strategy comes from the physiological constraints governing drug absorption into intestinal lymphatics after oral administration. The majority of orally administered small molecule drugs (such as FTC) are in fact taken up into blood stream (as opposed to lymph) from the enterocyte, as a result of its higher flow rate (500 times higher than lymph). Instead, highly lipophilic compounds (Log D7.4 > 5), with appropriate physicochemical properties, and high triglyceride solubility can undergo intestinal lymphatic transport upon being co-administered with lipids. This occurs as a result of the association of the lipophilic drug with chylomicrons. This project therefore aimed to use this physiological route to improve the delivery of FTC to the HIV reservoirs within mesenteric lymph nodes. Initially, a HPLC-UV analytical method for FTC determination in rat plasma was developed, achieving a limit of quantification of 10 ng/mL and linearity over a 10-12,000 ng/mL range. FTC’s potential for intestinal lymphatic targeting was assessed in silico, using a previously published model, and in vitro, based on the compound’s solubility in olive oil (triglyceride solubility) and its ability to associate with artificial chylomicrons. Both in silico and in vitro screenings showed negligible association and negligeable solubility in oil, therefore low predicted intestinal lymphatic transport. Pharmacokinetics and biodistribution studies were performed on FTC (dosed at 20 mg/kg to male Sprague Dawley rats) to assess its pharmacokinetics parameters and confirm the in vitro findings on intestinal lymphatic targeting. Orally administered animals were divided into two groups: a lipid-based group administered with drug and olive oil (1 mL/kg), and a lipid-free group administered with drug only. After oral administration in the lipid-free group, the drug showed a relatively short half-life (2.7 ± 0.6 h), with tmax observed either at 0.5 or 1 h. Co-administration of lipids led to a broadly comparable pharmacokinetic profile. The biodistribution study was conducted at both the observed tmax and at 2 h. Unexpectedly, in the lipid-based group the drug showed significantly higher concentrations in mesenteric lymph nodes than in blood at 1 and 2 h, and significantly higher tissue:blood ratio than almost any other lymph node at 0.5 and 2 h (range 1.76-3.15 folds higher depending on the node). This behaviour was reproducible also without the co-administration of lipids suggesting that it was not driven by chylomicron association. A library of lipophilic prodrugs of FTC with high in silico predicted lymphatic transport was subsequently designed and synthesised. In addition to the in vitro screening conducted for the parent compound for assessment of intestinal lymphatic transport potential, prodrugs were evaluated for their stability in gastro-intestinal tract and their ability to cleave in lymph. The former was done with a fasted simulated intestinal fluid (FaSSIF) with added esterase activity in vitro model, the latter by using a rat plasma model. The results showed that all prodrugs had a higher association with artificial chylomicrons than the parent drug. Furthermore, ester prodrugs with saturated promoieties had the most prolonged in vitro stability in gastrointestinal- and in lymph-mimicked environments, but low triglyceride solubility. In contrast, ester prodrugs with unsaturated promoieties showed the highest triglyceride solubility but limited stability in gastrointestinal and lymph-mimicked environments. The amide prodrug synthesised (a stearic acid derivative) showed poor stability in gastrointestinal-mimicked environment, as well as limited solubility in olive oil. The carbamate prodrugs investigated (an oleyl alcohol derivative and a saturated self-immolative derivative), on the other hand, showed to selectively cleave in plasma and remain unmodified in FaSSIF with added esterase activity over long periods, while having relatively high oil solubility. This made them good candidates to take further for in vivo studies. Among them, the oleyl alcohol derivative CA2 was selected because of the ease of synthesis and higher chylomicron association. In vivo pharmacokinetics studies showed that the parent drug release from the CA2 prodrug occurred rapidly: the prodrug was not detected following both lipid-based and lipid-free oral administration and was measurable only up to 3 h after intravenous dosing. The findings were consistent with the rapid release in plasma predicted in vitro. The absorption was slower than for unmodified FTC, with tmax 2 ± 1 h. Compared to unmodified FTC, AUC and Cmax achieved after administration of prodrug CA2 were lower, (in oral lipid-based group for unmodified FTC 15149 ± 2011 h*ng/mL and 5599 ± 587 ng/mL respectively vs for FTC released from CA2 6424 ± 917 h*ng/mL and 1594 ± 293 ng/mL). As a result, the FTC bioavailability almost halved from 99% to 61% after prodrug administration. In vivo biodistribution studies showed that the concentrations of FTC achieved after CA2 administration were significantly lower than those achieved by unmodified FTC in all lymph nodes and organs analysed, including mesenteric lymph nodes. Notably, when tissue:plasma ratios were examined after 2 h from administration, these differences were no longer statistically significant. Furthermore, intact prodrug was present in lymph, suggesting that in vivo conversion proceeded slower than in in vitro predictions. Overall, this project provided new insights into the biodistribution of FTC in different lymph nodes and demonstrated the potential of using prodrugs with a carbamate promoiety for a selective release in lymph and long stability in gastointestinal-tract.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7217120482
Cites:
Cited by:
Related to: 10